D3 Bio’s First‑Line Data Shows Landmark Efficacy of Elisrasib in KRAS G12C‑Positive NSCLC
iPAX‑2 Trial of TLX101 TX in First‑Line Glioblastoma Finishes Enrollment and Locks In Dosing Schedule